SCHEMBL5413783

SCHEMBL5413783

CNc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1NC(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ TP53 P04637 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ AURKA O14965 6/20 0.50
▸ HDAC1 Q13547 4/20 0.50
▸ JAK2 O60674 1/20 0.50
▸ LRRK2 Q5S007 1/20 0.50
▸ CDK2 P24941 1/20 0.50
▸ AURKB Q96GD4 1/20 0.50
▸ HDAC3 O15379 1/20 0.50
▸ HDAC2 Q92769 1/20 0.50
▸ HDAC6 Q9UBN7 1/20 0.50
▸ PDGFRB P09619 1/20 0.48
▸ PDGFRA P16234 1/20 0.48
▸ JAK1 P23458 2/20 0.48
▸ BRD4 O60885 1/20 0.48
▸ PTK2 Q05397 1/20 0.47
▸ GRM4 Q14833 1/20 0.47
▸ ALK Q9UM73 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5415421 0.87 STK17A (0.48) AURKAHDAC1JAK2LRRK2AURKB
SCHEMBL5415948 0.85 HDAC3 (0.49) MAPTAURKAHDAC1JAK2LRRK2
SCHEMBL5408068 0.85 LRRK2 (0.47) TP53MAPTAURKAHDAC1JAK2
SCHEMBL5408198 0.84 HDAC3 (0.48) NPC1RAB9AHDAC1JAK2LRRK2
SCHEMBL5418427 0.84 HDAC3 (0.47) HDAC1JAK2LRRK2HDAC3HDAC2
SCHEMBL5410091 0.83 APEX1 (0.53) HDAC1JAK2LRRK2HDAC3HDAC2
SCHEMBL5413822 0.83 CYP3A4 (0.53) MAPTHDAC1JAK2LRRK2HDAC3
SCHEMBL5416137 0.83 HDAC3 (0.46) HDAC1JAK2LRRK2HDAC3HDAC2
SCHEMBL5409821 0.82 MEN1 (0.53) NPC1RAB9AMAPTJAK2LRRK2
SCHEMBL5416062 0.82 STK17A (0.44) HDAC1JAK2LRRK2HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 NPC1 679/4885RAB9A 1793/4885TP53 1261/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 NPC1 1758/4885RAB9A 1327/4885TP53 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback